

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
01 May 2025 (01.05.2025)



(10) International Publication Number  
**WO 2025/087264 A1**

(51) International Patent Classification:

*A61K 47/68* (2017.01) *C07K 16/28* (2006.01)  
*A61K 31/4745* (2006.01) *A61P 35/00* (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2024/126637

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

23 October 2024 (23.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/592304 23 October 2023 (23.10.2023) US

(71) Applicants: **HANSOHO BIO LLC** [US/US]; Hansoh Bio, 9900 Medical Center Drive, Ste 200, Rockville, Maryland 20850 (US). **SHANGHAI HANSOHO BIOMEDICAL CO., LTD.** [CN/CN]; Building 11, No.3728 Jinke Road, (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 201203 (CN). **CHANGZHOU HANSOHO PHARMACEUTICAL CO., LTD.** [CN/CN]; 1028 Liaohe Road, Xinbei District, Changzhou, Jiangsu 213001 (CN).

(72) Inventors: **LI, Qing**; Hansoh Bio, 9900 Medical Center Drive, Ste 200, Rockville, Maryland 20850 (US). **ZHOU, Ningyun**; Hansoh Bio, 9900 Medical Center Drive, Ste 200, Rockville, Maryland 20850 (US).

(74) Agent: **GE CHENG & CO., LTD.**; Level 10, Tower E3, The Towers, Oriental Plaza, No. 1, East Chang An Avenue, Dongcheng District, Beijing 100738 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: LIGAND-CYTOTOXICITY DRUG CONJUGATES AND PHARMACEUTICAL USES THEREOF

(57) Abstract: To provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an anti-cadherin 17 antibody comprising a heavy chain variable region and a light chain variable region, a drug conjugate thereof, and a composition containing the anti-cadherin 17 antibody or the drug conjugate thereof, and an application thereof as a drug.

WO 2025/087264 A1